Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Pharmaxis agrees key CF trial parameters with FDA on Bronchitol

Pharmaxis has concluded a productive end to the review meeting with the United States FDA.

Pharmaxis announces outcome of business review

Pharmaxis has announced a revised business plan that delivers significant reductions in expenses and increases the focus on partnering strategies.

Pharmaxis announces US$40 million financing agreement with NovaQuest

Pharmaxis is pleased to announce the signing of a Financing Agreement with NovaQuest under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for CF in the EU and US.

Pharmaxis appoints Gary Phillips as new CEO

The Pharmaxis board has appointed Mr. Gary Phillips to the position of Chief Executive Officer.